Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite
Abstract
Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite var callbackToken='475B5DDB295DAA5'; Skip to main page content HOME CURRENT ISSUE ARCHIVE FEEDBACK SUBSCRIPTIONS ALERTS HELP Keywords GO Advanced » Institution: DeepDyve Sign In as Member / Individual User Name Password Sign In Metabolism of LY654322, a Growth Hormone Secretagogue, to an Unusual Diimidazopyridine Metabolite Anthony G. Borel , Timothy M. Jones , Robert J. Barbuch , David A. Jackson , Palaniappan Kulanthaivel , Edward Mattiuz , Valentine J. Klimkowski , William J. Wheeler 1 and Gregory A. Rener Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana <h3>Address correspondence to:</h3> Dr. Anthony G. Borel, Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: aborel@lilly.com ↵ 1 Current affiliation: IsotopicSolutions, LLC, Indianapolis, Indiana. <h2>Abstract</h2> 2-Methylalanyl- N -{1-[(1 R )-1-(4-fluorophenyl)-1-methyl-2-oxo-2-pyrrolidin-1-ylethyl]-1 H -imidazol-4-yl}-5-phenyl- d -norvalinamide (LY654322) was rapidly cleared in rats and dogs by renal excretion of parent and metabolism (oxidative and hydrolytic). Among the metabolites identified in the urine of rats and dogs was M25, which was structurally unusual. Indeed, the characterization of M25 and investigation into its disposition relied on the convergence of diverse analytical methodologies. M25 eluted